Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells

Haematologica

Volumn 97, Issue 6, 2012, Pages 943-951

  Fernández Calotti, Paula X ^a   Lopez Guerra, Mónica ^b   Colomer, Dolors ^b   Pastor Anglada, Marçal ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Chronic lymphocytic leukemia; Fludarabine; hCNT3; Nucleoside; Treatment

Indexed keywords

BORTEZOMIB; CD19 ANTIGEN; CD38 ANTIGEN; CD5 ANTIGEN; DEXAMETHASONE; FLUDARABINE; HIGH AFFINITY FLUDARABINE TRANSPORTER 3; NUCLEOSIDE TRANSPORTER; PROTEIN KINASE ZAP 70; PROTEIN P53; RETINOIC ACID; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MUTATIONAL ANALYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; AGED, 80 AND OVER; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PRIMARY CELL CULTURE; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRETINOIN; TRITIUM; VIDARABINE;

EID: 84862256377     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.051557     Document Type: Article

References (44)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-15.
2. Keating M, Kantarjian H, Talpaz M, Redman J, Koller C. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74:19-25.
3. Elter T, Hallek M, Engert A. Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother. 2006;7:1641-51.
4. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3(7): 415-24.
5. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia. 2001;15(6):875-90.
6. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990;17:3-17.
7. Plunkett W, Saunders PP. Metabolism and action of purine nucleoside analogs. Pharmacol Ther. 1991;49(3):239-68.
8. Zhu Q, Tan DC, Samuel M, Chan ES, Linn YC. Fludarabine in comparison to alkylatorbased regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis. Leuk Lymphoma. 2004;45(11):2239-45.
9. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet. 2007;370 (9583):230-9.
10. Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989;74(1):19-25.
11. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE. Long-term followup of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92(4): 1165-71.
12. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793-8.
13. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107(3):885-91.
14. Weiss MA, Glenn M, Maslak P, Rahman Z, Noy A, Zelenetz A, et al. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy. Leukemia. 2000;14(9):1577-82.
15. Laurenti L, Tarnani M, De Padua L, Efremov DG, Zini G, Garzia M, et al. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. Ann Hematol. 2008;87(11):891-8.
16. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-74.
17. Hillmen P. Chronic lymphocytic leukaemia-moving towards cure? Lancet. 2010;376 (9747):1122-4.
18. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1756-65.
19. Dohner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G. P53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B cell leukemias. Blood. 1995;85(6):1580-9.
20. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup phase III trial E2997. J Clin Oncol. 2007; 25(7):799-804.
21. Bosch F, Ferrer A, Villamor N, Gonzalez M, Briones J, Gonzalez Barca E. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronoc lymphocytic leukemia: high response rate and disease aradication. Clin Can Res. 2008;14(1):155-61.
22. Pettitt AR, Clarke AR, Cawley JC, Griffiths SD. Purine analogs kill resting lymphocytes by p53 dependent and independent mechanisms. Br J Haematol. 1999;105(4):986-8.
23. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114(20):4441-50.
24. Klopfer A, Hasenjager A, Belka C, Schulze-Osthoff K, Dorken B, Daniel PT. Adenine deoxynucleotides fludarabine and cladribine induce apoptosis in a CD95/Fas receptor, FADD and caspase-8-independent manner by activation of the mitochondrial cell death pathway. Oncogene. 2004;23 (58):9408-18.
25. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004;447(5):735-43.
26. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch. 2004;447(5):728-34.
27. Molina-Arcas M, Bellosillo B, Casado FJ, Montserrat E, Gil J, Colomer D, et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood. 2003;101(6):2328-34.
28. Pastor-Anglada M, Molina-Arcas M, Casado FJ, Bellosillo B, Colomer D, Gil J. Nucleoside transporters in chronic lymphocytic leukaemia. Leukemia. 2004;18(3):385-93.
29. Ritzel MW, Ng AM, Yao SY, Graham K, Loewen SK, Smith KM, et al. Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem. 2001;276(4):2914-27.
30. Lang TT, Selner M, Young JD, Cass CE. Acquisition of human concentrative nucleoside transporter 2 (hcnt2) activity by gene transfer confers sensitivity to fluoropyrimidine nucleosides in drug-resistant leukemia cells. Mol Pharmacol. 2001;60(5):1143-52.
31. Mackey JR, Galmarini CM, Graham KA, Joy AA, Delmer A, Dabbagh L, et al. Quantitative analysis of nucleoside transporter and metabolism gene expression in chronic lymphocytic leukemia (CLL): identification of fludarabine-sensitive and-insensitive populations. Blood. 2005;105(2): 767-74.
32. Chomienne C, Ballerini P, Balitrand N, Daniel MT, Fenaux P, Castaigne S, et al. All trans-retinoic acid in promyelocytic leukemias. II. In vitro studies structure function relationship. Blood. 1990;76:1710-8.
33. Fernandez Calotti P, Pastor Angada M. Alltrans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism. J Biol Chem. 2010;285(18):13589-98.
34. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111 (12):5446-56.
35. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003; 348(18):1764-75.
36. Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007;21(1): 1-3.
37. Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Bosch F, Campo E, et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood. 2002;100(5):1810-6.
38. Mercader J, Gomez-Angelats M, del Santo B, Casado FJ, Felipe A, Pastor-Anglada M. Nucleoside uptake in rat liver parenchymal cells. Biochem J 1996;317:835-842.
39. Poggi A, Venturino C, Catellani S, Clavio M, Miglino M, Gobbi M, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Reasearch. 2004;64:9172-9.
40. Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2009;115(13):2824-36.
41. Abrisqueta P, Crespo M, Bosch F. Personalizing treatment for chronic lymphocytic leukemia. Expert Rev Hematol. 2011;4(1):27-35.
42. Tsang R, Santos C, Ghosh S, Dabbagh L, King K, Young J, et al. Immunohistochemistry for human concentrative nucleoside transporter 3 protein predicts fludarabine sensitivity in chronic lymphocytic leukemia. Mod Pathol. 2008;21 (11):1387-93.
43. Pepper C, Ali K, Thomas A, Hoy T, Fegan C, Chowdary P, et al. Retinoid-induced apoptosis in B-cell chronic lymphocytic leukaemia cells is mediated through caspase-3 activation and is independent of p53, the retinoic acid receptor, and differentiation. Eur J Haematol. 2002;69:227-35.
44. Errasti Murrugarren E, Pastor Anglada M, Casado J. Role of CNT3 in the transepithelial flux of nucleosides and nucleosidederived drugs. J Physiol. 2007; 582:1249-60.